Question explored with the scientific record
knee replacement
The short version: knee replacement is a real surgery with real risks, and the pain management evidence is thinner than most surgeons let on.
The retrieved studies focus almost entirely on postoperative pain control and blood clot prevention, not on whether the surgery itself is worth it. That matters. The evidence shows the expensive options often do not beat the cheap ones. Liposomal bupivacaine, which costs about $402 per dose, worked no better than a $16 standard injection for pain or narcotic use in a randomized trial [1]. A 2025 systematic review found NSAIDs and acetaminophen are the validated workhorses, while opioids, gabapentinoids, and steroids showed limited or uncertain acute benefit [2]. Preoperative nerve ablation did nothing for pain, opioid use, or function up to six months after surgery in a sham-controlled trial [3]. Acupuncture did cut fentanyl use by about 28% and nausea by a large margin in one blinded trial [4].
The clot risk is real and often understated. One meta-analysis found female patients have a slightly higher venous thromboembolism risk after knee replacement [5]. Doing both knees at once roughly doubles the clot risk and quadruples the bleeding risk compared to one knee at a time [6]. A nationwide Taiwanese study of over 113,000 patients found symptomatic clots in only about 0.5% of people even with almost no blood thinners used, which raises a hard question about whether universal prophylaxis is necessary [8]. The newer factor XI inhibitor outperformed enoxaparin in one trial, with a 4% clot rate versus 30%, and less bleeding [7], but that is one industry-funded phase 2 study.
Infection is the nightmare scenario. About 1-2% of knee replacements get infected per year [12]. When that happens, simple washout procedures fail roughly half the time, with one multicenter study showing a 57% failure rate at four years [9]. A prior failed washout doubles the risk of recurrence after the two-stage revision that follows [11]. Two-stage revision itself only clears infection about 69-81% of the time [10][11]. The mortality in recurrent infections can reach 45% [12]. That is the number to sit with before agreeing to surgery.
| Complication | Rate or finding | Source |
|---|---|---|
| Symptomatic VTE without prophylaxis | ~0.5% (Taiwan, 113,844 patients) | [8] |
| VTE after bilateral vs unilateral TKA | ~2x higher risk | [6] |
| Bleeding after bilateral vs unilateral TKA | ~4x higher risk | [6] |
| PJI after TKA | 1-2% per year | [12] |
| DAIR failure for infected TKA | 57% at 4 years | [9] |
| Two-stage revision success | 69-81% | [10][11] |
The evidence base has structural holes. Most of these studies are single-center, short-term, and focused on surrogate endpoints like pain scores rather than long-term function or survival. The 2025 systematic review is the most honest document here, admitting that many "effective" pain drugs fail to reach clinically meaningful thresholds [2]. Nobody in this retrieval compared knee replacement against a rigorous non-surgical program of exercise, weight loss, and anti-inflammatory diet over five years. That comparison is the one that would actually tell you if the surgery is worth it.
My call: knee replacement can help severe arthritis, but the pain management evidence favors cheap, simple approaches over expensive ones, and the infection and clot risks are serious enough that you should exhaust non-surgical options first. Confidence: moderate.
Sources used 12
-
The AAHKS Clinical Research Award: Liposomal Bupivacaine and Periarticular Injection Are Not Superior to Single-Shot Intra-articular Injection for Pain Control in Total Knee Arthroplasty
In a single-center, three-arm randomized trial of unilateral total knee arthroplasty, liposomal bupivacaine and periarticular injections did not improve postoperative pain control or reduce narcotic use compared with a standard intra-articular bupivacaine/morphine injection, and…
DOI: 10.1016/j.arth.2016.03.036 -
Pharmacologic pain management strategies for reducing postoperative pain in total knee arthroplasty: a systematic review from molecular mechanisms to clinical efficiency
This systematic review synthesizes evidence on pharmacologic pain management strategies after total knee arthroplasty, finding NSAIDs and acetaminophen as validated components of multimodal analgesia, with duloxetine showing potential but requiring larger trials, while opioids, …
DOI: 10.1007/s00402-025-06049-7 -
Radiofrequency ablation of genicular nerves prior to total knee replacement has no effect on postoperative pain outcomes: a prospective randomized sham-controlled trial with 6-month follow-up
Preoperative cooled genicular nerve radiofrequency ablation before total knee arthroplasty did not improve postoperative pain, opioid consumption, or function up to 6 months after surgery.
DOI: 10.1136/rapm-2018-100094 -
Acupuncture for Pain Relief After Total Knee Arthroplasty
A randomized, patient-evaluator blinded trial comparing true acupuncture (knee and scalp electroacupuncture plus auricular acupuncture) to sham auricular acupuncture after total knee arthroplasty showed reduced postoperative fentanyl use, longer time to first analgesic request, …
DOI: 10.1097/aap.0000000000000138 -
Gender differences of venous thromboembolism risk after total hip and total knee arthroplasty: a meta-analysis
This meta-analysis evaluates gender differences in the risk of venous thromboembolism (VTE) following total hip and knee arthroplasties, finding that female patients have a slightly higher risk than male patients.
DOI: 10.1007/s11239-015-1283-6 -
Comparing the 30-Day Risk of Venous Thromboembolism and Bleeding in Simultaneous Bilateral vs Unilateral Total Knee Arthroplasty
This study analyzes the 30-day risk of venous thromboembolism and bleeding in patients undergoing simultaneous bilateral total knee arthroplasty compared to unilateral total knee arthroplasty, finding that SBTKA significantly increases the risk of these complications without aff…
DOI: 10.1016/j.arth.2018.06.002 -
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
A phase 2 randomized open-label trial showing that a Factor XI antisense oligonucleotide (FXI-ASO) lowers FXI levels and reduces postoperative venous thromboembolism in elective total knee arthroplasty, with the 300 mg dose outperforming enoxaparin and a favorable bleeding profi…
DOI: 10.1056/nejmoa1405760 -
Universal pharmacological thromboprophylaxis for total knee arthroplasty may not be necessary in low‐risk populations: a nationwide study in Taiwan
This nationwide study in Taiwan found that universal pharmacological thromboprophylaxis for total knee arthroplasty may not be necessary in low-risk populations, as the incidence of symptomatic venous thromboembolism (VTE) was low despite a very low rate of thromboprophylaxis us…
DOI: 10.1111/j.1538-7836.2011.04555.x -
A Multicenter Study of Irrigation and Debridement in Total Knee Arthroplasty Periprosthetic Joint Infection: Treatment Failure Is High
This multicenter observational study investigates the high failure rates of irrigation and debridement (I&D) with component retention in total knee arthroplasty periprosthetic joint infection (PJI), revealing a 57.4% failure rate at four years and identifying time symptomatic an…
DOI: 10.1016/j.arth.2017.11.029 -
Outcomes of infected revision knee arthroplasty managed by two-stage revision in a tertiary referral centre
This study evaluates the outcomes of 51 patients with infected total knee arthroplasties managed by two-stage revision, revealing a 69% success rate in eradicating infection, with significant associations found between multidrug resistance and unsuccessful outcomes.
DOI: 10.1016/j.knee.2014.10.005 -
Does Prior Failed Debridement Compromise the Outcome of Subsequent Two-Stage Revision Done for Periprosthetic Joint Infection Following Total Knee Arthroplasty?
This retrospective study of 184 knees undergoing two-stage revision for deep peri-prosthetic knee infection compares outcomes between patients with a prior failed DAIR and those who had direct two-stage revision, finding that prior failed DAIR doubles the risk of infection recur…
DOI: 10.1016/j.arth.2018.02.087 -
Periprosthetic joint infection
This is a comprehensive narrative review summarizing the epidemiology, risk factors, preventive measures, diagnostic approaches, and treatment options for periprosthetic joint infection after total joint arthroplasty, highlighting the ongoing burden, key prevention strategies, a…
DOI: 10.1016/S0140-6736(14)61798-0